Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsDividends payablesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PharmaCyte Biotech (PMCB) Total Liabilities (2016 - 2026)

PharmaCyte Biotech (PMCB) has disclosed Total Liabilities for 15 consecutive years, with $19.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Liabilities rose 66.76% to $19.4 million in Q4 2025 year-over-year; TTM through Oct 2025 was $19.4 million, a 66.76% increase, with the full-year FY2025 number at $3.3 million, down 83.93% from a year prior.
  • Total Liabilities was $19.4 million for Q4 2025 at PharmaCyte Biotech, up from $1.5 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $22.5 million in Q1 2024 to a low of $186122.0 in Q4 2021.
  • A 5-year average of $7.4 million and a median of $1.4 million in 2022 define the central range for Total Liabilities.
  • Peak YoY movement for Total Liabilities: skyrocketed 3375.95% in 2024, then crashed 91.15% in 2025.
  • PharmaCyte Biotech's Total Liabilities stood at $186122.0 in 2021, then surged by 604.45% to $1.3 million in 2022, then skyrocketed by 1487.38% to $20.8 million in 2023, then plummeted by 44.04% to $11.6 million in 2024, then surged by 66.76% to $19.4 million in 2025.
  • Per Business Quant, the three most recent readings for PMCB's Total Liabilities are $19.4 million (Q4 2025), $1.5 million (Q3 2025), and $3.3 million (Q2 2025).